228 related articles for article (PubMed ID: 15364150)
1. Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study.
Greenberg D; Bakhai A; Neumann PJ; Cohen DJ
Health Policy; 2004 Nov; 70(2):207-16. PubMed ID: 15364150
[TBL] [Abstract][Full Text] [Related]
2. Willingness to pay to eliminate the risk of restenosis following percutaneous coronary intervention: a contingent valuation.
Guertin JR; Liu A; Abrahamowicz M; Cohen DJ; Ismail S; LeLorier J; Brophy JM; Rinfret S
Circ Cardiovasc Qual Outcomes; 2011 Jan; 4(1):46-52. PubMed ID: 21156881
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of medicare claims data.
Clark MA; Bakhai A; Lacey MJ; Pelletier EM; Cohen DJ
Circulation; 2004 Jul; 110(3):259-64. PubMed ID: 15226211
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic effects of coronary restenosis after percutaneous coronary intervention in a managed care population.
Clark MA; Bakhai A; Pelletier EM; Cohen DJ
Manag Care; 2005 Apr; 14(4):42-4, 46-51. PubMed ID: 15898211
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
6. Valuing a hypothetical cure for rheumatoid arthritis using the contingent valuation methodology: the patient perspective.
Fautrel B; Clarke AE; Guillemin F; Adam V; St-Pierre Y; Panaritis T; Fortin PR; Menard HA; Donaldson C; Penrod JR
J Rheumatol; 2005 Mar; 32(3):443-53. PubMed ID: 15742435
[TBL] [Abstract][Full Text] [Related]
7. Using the risk of restenosis as a guide to triaging patients between surgical and percutaneous coronary revascularization.
Kettelkamp R; House J; Garg M; Stuart RS; Grantham A; Spertus J
Circulation; 2004 Sep; 110(11 Suppl 1):II50-4. PubMed ID: 15364838
[TBL] [Abstract][Full Text] [Related]
8. Physicians' perceptions towards the impact of and willingness to pay for clinical computerization in Hong Kong.
Leung GM; Yeung RY; Lai TY; Johnston JM; Tin KY; Wong IO; Woo PP; Ho LM
Int J Med Inform; 2004 Jun; 73(5):403-14. PubMed ID: 15171982
[TBL] [Abstract][Full Text] [Related]
9. Temporal trends in target vessel revascularization in clinical practice: long-term outcomes following coronary stenting from the Duke Database for Cardiovascular Disease.
Kandzari DE; Tuttle RH; Zidar JP; Jollis JG
J Invasive Cardiol; 2006 Sep; 18(9):398-402. PubMed ID: 16954575
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
[TBL] [Abstract][Full Text] [Related]
11. Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program.
Ryan J; Linde-Zwirble W; Engelhart L; Cooper L; Cohen DJ
Circulation; 2009 Feb; 119(7):952-61. PubMed ID: 19204307
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with prior percutaneous revascularization undergoing repeat coronary intervention (from the PRESTO Trial).
Arjomand H; Willerson JT; Holmes DR; Bamlet WR; Surabhi SK; Roukoz B; Espinoza A; McClelland RL; McCormick DJ; Goldberg S;
Am J Cardiol; 2005 Sep; 96(6):741-6. PubMed ID: 16169350
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients.
Stroupe KT; Morrison DA; Hlatky MA; Barnett PG; Cao L; Lyttle C; Hynes DM; Henderson WG;
Circulation; 2006 Sep; 114(12):1251-7. PubMed ID: 16966588
[TBL] [Abstract][Full Text] [Related]
15. Willingness to pay for health improvements of physical activity on prescription.
Romé A; Persson U; Ekdahl C; Gard G
Scand J Public Health; 2010 Mar; 38(2):151-9. PubMed ID: 20064920
[TBL] [Abstract][Full Text] [Related]
16. Percutaneous coronary intervention for chronic total occlusions: the Thoraxcenter experience 1992-2002.
Hoye A; van Domburg RT; Sonnenschein K; Serruys PW
Eur Heart J; 2005 Dec; 26(24):2630-6. PubMed ID: 16183693
[TBL] [Abstract][Full Text] [Related]
17. Hybrid coronary revascularization in the era of drug-eluting stents.
Murphy GJ; Bryan AJ; Angelini GD
Ann Thorac Surg; 2004 Nov; 78(5):1861-7. PubMed ID: 15511503
[TBL] [Abstract][Full Text] [Related]
18. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS).
Ix JH; Mercado N; Shlipak MG; Lemos PA; Boersma E; Lindeboom W; O'Neill WW; Wijns W; Serruys PW
Am Heart J; 2005 Mar; 149(3):512-9. PubMed ID: 15864241
[TBL] [Abstract][Full Text] [Related]
19. Willingness-to-pay for community-based insurance in Burkina Faso.
Dong H; Kouyate B; Cairns J; Mugisha F; Sauerborn R
Health Econ; 2003 Oct; 12(10):849-62. PubMed ID: 14508869
[TBL] [Abstract][Full Text] [Related]
20. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease.
van Domburg RT; Lemos PA; Takkenberg JJ; Liu TK; van Herwerden LA; Arampatzis CA; Smits PC; Daemen J; Venema AC; Serruys PW; Bogers AJ
Eur Heart J; 2005 Apr; 26(7):675-81. PubMed ID: 15637087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
